, Volume 37, Issue 2, pp 217–221 | Cite as

Pathogenesis of Type 2 (non-insulin-dependent) diabetes mellitus: the role of skeletal muscle glucose uptake and hepatic glucose production in the development of hyperglycaemia. A critical comment

  • H. Beck-Nielsen
  • O. Hother-Nielsen
  • A. Vaag
  • F. Alford
For debate


Our understanding of the pathophysiology of Type 2 diabetes has advanced considerably over the last decade, but many problems and issues remain unresolved. The initiation of this debate mirrors many of the problems that we face today. An understanding of the primary and secondary defects leading to diabetes in “genetically prone” individuals are of crucial importance to further our understanding of the metabolic process involved in the development of the diabetic state. In our contribution to this debate we have pointed out the methodological problems that have arisen in the estimation of HGP and the quantitation of glucose kinetics in normo-and hyperglycaemic Type 2 diabetic individuals. These problems are not yet completely resolved. Therefore, the importance of the liver vs the importance of muscle glucose metabolism in the development of hyperglycaemia will probably have to wait for new and improved techniques. However, the current data strongly indicate that the primary defect (genetic defect?) in insulin action is located to skeletal muscles.

The near-normal HGP values in Type 2 diabetes patients with fasting blood glucose values less than 12–15 mmol/1 do not indicate that the insulin sensitivity of liver is normal in Type 2 diabetes, but proves to us that the reduction in insulin action in both liver and muscles are fully compensated —perhaps slightly overcompensated.


  1. 1.
    Gerich JE (1991) Is muscle the major site of insulin resistance in type 2 (non-insulin-dependent) diabetes mellitus? Diabetologia 34: 607–610PubMedCrossRefGoogle Scholar
  2. 2.
    DeFronzo RA (1992) Pathogenesis of type 2 (non-insulindependent) diabetes mellitus: a balanced overview. Diabetologia 35: 389–397PubMedCrossRefGoogle Scholar
  3. 3.
    Hother-Nielsen O, Beck-Nielsen H (1991) Insulin resistance, but normal basal rates of glucose production in patients with newly diagnosed mild diabetes mellitus. Acta Endocrinol (Copenh) 124: 637–645Google Scholar
  4. 4.
    Hother-Nielsen O, Beck-Nielsen H (1990) On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes using primed-continuous 3-3H-glucose infusion. Diabetologia 33: 603–610PubMedCrossRefGoogle Scholar
  5. 5.
    Vaag A, Skött P, Damsbo P, Gall M-A, Richter EA, Beck-Nielsen H (1991) Effect of anti-lipolytic nicotinic acid analogue acipimox on whole body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 88: 1282–1290PubMedCrossRefGoogle Scholar
  6. 6.
    DeFronzo RA, Gunnarson R, Bjorkman O, Olsson M, Wahren J (1985) Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin-dependent (type II) diabetes mellitus. J Clin Invest 76: 149–155PubMedCrossRefGoogle Scholar
  7. 7.
    Capaldo B, Napoli R, DiMarino L, Picardi A, Riccardi G, Sacca L (1988) Quantitation of forearm glucose and free fatty acid (FFA) disposal in normal subjects and type II diabetic patients: evidence against an essential role for FFA in the pathogenesis of insulin resistance. J Clin Endocrinol Metab 67: 893–898PubMedGoogle Scholar
  8. 8.
    Damsbo P, Vaag A, Hother-Nielsen O, Beck-Nielsen H (1991) Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34: 239–245PubMedCrossRefGoogle Scholar
  9. 9.
    Hother-Nielsen O, Beck-Nielsen H (1991) Basal glucose metabolism in type 2 diabetes: a critical review. Diabete Metab 17: 136–145PubMedGoogle Scholar
  10. 10.
    DeFronzo RA, Simonson D, Ferrannini E (1982) Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type I (insulin-dependent) diabetes mellitus. Diabetologia 23: 313–319PubMedCrossRefGoogle Scholar
  11. 11.
    Hother-Nielsen O, Schmitz O, Andersen PH, Pedersen O, Beck-Nielsen H (1988) In vivo action of glibenclamide in obese subjects with mild type 2 (non-insulin-dependent) diabetes. Diabetes Res 8: 63–70PubMedGoogle Scholar
  12. 12.
    Vaag A, Damsbo P, Hother-Nielsen O, Beck-Nielsen H (1992) Hyperglycaemia compensates for the defects in insulin-mediated glucose metabolism and in the activation of glycogen synthase in the skeletal muscle of patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35: 80–88PubMedCrossRefGoogle Scholar
  13. 13.
    Boden G, Ray JK, Smith RH, Owen OE (1983) Carbohydrate oxidation and storage in non-insulin dependent diabetic patients. Diabetes 32: 982–987PubMedCrossRefGoogle Scholar
  14. 14.
    Felber JP, Ferrannini E, Golay A et al. (1987) Role of lipid oxidation in the pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes 36: 1341–1350PubMedCrossRefGoogle Scholar
  15. 15.
    Kelley D, Mandarino L (1990) Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in noninsulin-dependent diabetes mellitus. J Clin Invest 86: 1999–2007PubMedCrossRefGoogle Scholar
  16. 16.
    Glauber H, Wallace P, Brechtel G (1987) Effects of fasting on plasma glucose and prolonged tracer measurement of hepatic glucose output in NIDDM. Diabetes 36: 1187–1194PubMedCrossRefGoogle Scholar
  17. 17.
    Chen Y-DI, Swislocki ALM, Jeng C-Y, Juang J-H, Reaven GM (1988) Effect of time on measurement of hepatic glucose production. J Clin Endocrinol Metab 67: 1084–1088PubMedGoogle Scholar
  18. 18.
    Finegood DT, Bergman RN, Vranic M (1987) Estimation of endogenous glucose production during hyperinsulinemiceuglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 36: 914–924PubMedCrossRefGoogle Scholar
  19. 19.
    Hother-Nielsen O, Mengel A, Møller J, Rasmussen O, Schmitz O, Beck-Nielsen H (1992) Assessment of glucose turnover rates in euglycaemic clamp studies using primedconstant [3-3H]-glucose infusion and labelled or unlabelled glucose infusates. Diabetic Med 9: 840–849PubMedCrossRefGoogle Scholar
  20. 20.
    Proietto J, Alford FP, Dudley FJ (1980) The mechanism of carbohydrate intolerance of cirrhosis. J Clin Endocrinol Metab 51: 1030–1036PubMedGoogle Scholar
  21. 21.
    Beck-Nielsen H, Vaag A, Damsbo P et al. (1992) Insulin resistance in skeletal muscles in patients with NIDDM. Diabetes Care 15: 418–429PubMedCrossRefGoogle Scholar
  22. 22.
    Vaag A, Henriksen JE, Beck-Nielsen H (1992) Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest 89: 782–788PubMedCrossRefGoogle Scholar
  23. 23.
    Eriksson J. Franssila-Kallunki A, Ekstrand A et al. (1989) Early metabolic defects in persons at increased risk for noninsulin-dependent diabetes mellitus. N Engl J Med 6: 337–343CrossRefGoogle Scholar
  24. 24.
    Gullig, Ferrannini E, Stern M, Haffner S, DeFronzo R (1992) The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 41: 1575–1586CrossRefGoogle Scholar
  25. 25.
    Magnusson I, Tothman LD, Katz L, Shulman RG, Shulman GI (1992) Increased rate of gluconeogenesis in type II diabetes mellitus. J Clin Invest 90: 1323–1327PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • H. Beck-Nielsen
    • 1
  • O. Hother-Nielsen
    • 1
  • A. Vaag
    • 1
  • F. Alford
    • 2
  1. 1.Department of Internal MedicineM, Odense University HospitalOdense CDenmark
  2. 2.Department of EndocrinologySt. Vincent’s HospitalMelbourneAustralia

Personalised recommendations